Adding IO Biotech’s lead candidate, IO102, to first-line treatment with Keytruda (pembrolizumab) is likely to result in better response rates in people with metastatic non-small cell lung cancer (NSCLC), an interim analysis of a Phase 2 trial showed. The analysis, with predetermined requirements and called a futility analysis, determines whether a trial will likely meet its goals,…
To help minimize the threat of COVID-19 to themselves and others, healthy women at average risk should postpone breast cancer screening until later this year, Susan G. Komen recommends. However, the nonprofit organization emphasized that those experiencing breast cancer warning signs should alert their healthcare providers to assess the need for diagnostic imaging. Komen’s recommendation…
Moderate lifetime alcohol intake in middle-aged and older people who don’t show signs of dementia is associated with lower deposits of amyloid-beta, the protein that forms toxic aggregates in the brain and is thought to be involved in the onset of Alzheimer’s disease, a study from Korea found. The study, “Association of moderate alcohol intake…
Combining two methods of prostate biopsy — using one guided by magnetic resonance imaging (MRI) along with conventional ultrasound-guided biopsy — results in a more accurate detection of clinically significant prostate cancers than either method alone, a study shows. The researchers hope this combined method will improve clinicians’ current confidence levels in prostate cancer diagnosis…
Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors, a study in mice has found. These findings support further investigation into the process of autophagy, which is often abnormal in ovarian cancer patients, as a potential target…
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard treatment with Revlimid (lenalidomide), a new study shows. The study, “Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients,” was…
During this year’s Respiratory Effectiveness Group (REG) Summit (2016 REG Summit), researchers from around the globe highlighted the urgent need for more research into current therapies for chronic obstructive pulmonary disease (COPD). According to a news release, this concern is in line with the announcement by members of the World Health Organization (WHO) who stated that in…
GlaxoSmithKline (GSK) recently presented new data from a pre-specified analysis of the SUMMIT clinical trial, showing that once daily treatment with Breo Ellipta (fluticasone furoate/vilanterol) reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients compared to placebo. The presentation was one of two given at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, California. Breo Ellipta is an inhaled corticosteroid/long-acting…
The University of Texas MD Anderson Cancer Center has signed a contract with Elekta to acquire Elekta Infinity linear accelerators and brachytherapy afterloaders, as well as software and services. Elekta, which specializes in tools and systems to treat cancer and brain disorders, claims that its innovations are behind most of the critical technological advances in radiation oncology over the…
The U.S. Food and Drug Administration (FDA) has approved Harbour BioMed’s investigational new drug applications to initiate U.S. clinical trials testing two of its immunotherapy candidates — HBM9167 and HBM4003 — in several cancers. HBM9167 and HBM4003 are immune checkpoint inhibitors designed to boost the body’s anti-tumor responses by blocking the proteins that cancer cells use to…
